Similar articles

• Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

  Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA. Duggan DB, et al. J Clin Oncol. 2003 Feb 15;21(4):607-14. doi: 10.1200/JCO.2003.12.086. J Clin Oncol. 2003. PMID: 12586796 Clinical Trial.
• Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?

  Diehl V, Fuchs M; GHSG. Diehl V, et al. Transfus Apher Sci. 2007 Aug;37(1):37-41. doi: 10.1016/j.transci.2007.04.004. Epub 2007 Aug 21. Transfus Apher Sci. 2007. PMID: 17714996 Review.
• Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP.

  Santoro A, Viviani S, Villarreal CJ, Bonfante V, Delfino A, Valagussa P, Bonadonna G. Santoro A, et al. Cancer Treat Rep. 1986 Mar;70(3):343-8. Cancer Treat Rep. 1986. PMID: 2420444 Clinical Trial.
• Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.

  Piga A, Ambrosetti A, Todeschini G, Cetto G, Perona G, Cellerino R. Piga A, et al. Cancer Treat Rep. 1984 Jul-Aug;68(7-8):947-51. Cancer Treat Rep. 1984. PMID: 6204754
• [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].

  Arranz R, Gil-Fernández JJ, Muñoz E, Acevedo A, Sobrino MP, Fernández-Rañada JM. Arranz R, et al. Sangre (Barc). 1998 Jun;43(3):179-84. Sangre (Barc). 1998. PMID: 9741222 Review. Spanish.